Juno Therapeutics
Juno Therapeutics Inc was an American biopharmaceutical company founded in 2013 through a collaboration of the Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and pediatrics partner Seattle Children's Research Institute. The company was launched with an initial investment of $120 million, with a remit to develop a pipeline of cancer immunotherapy drugs. The company raised $300 million through private funding and a further $265 million through their IPO.
| Company type | Subsidiary |
|---|---|
| Industry | Biotechnology |
| Founded | 2013 |
| Headquarters | Seattle, WA |
Key people | Hans Bishop (CEO & President) Steve Harr, M.D. (CFO) |
| Parent | Bristol-Myers Squibb |
| Website | www |
On January 22, 2018, Juno Therapeutics was acquired by biotechnology company Celgene for $9 billion.
In November 2019, Bristol-Myers Squibb (BMS) announced that it has completed its acquisition of Celgene.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.